Retinal Vascular DisorderNCT02827071
Ocular Imaging Study Using Advanced OCT
An observational study of Retinal Vascular Disorder and Macular Degeneration, run by University of California, Los Angeles at 1 site in United States.
Trial summary
The purpose of this study is to evaluate this AngioScan angiography software on patients with various retinal vascular disorders. The advanced OCT instrument is an FDA approved clinically used camera, but the AngioScan angiography software is not FDA approved. Read more about this study
- Who is it for?
- Ages 18 to 115 years
- Conditions the study is for
- Retinal Vascular Disorder, Macular Degeneration
- How many people
- 150 participants
- Where
- 1 siteUnited States
- Study dates
- Jul 2016to 9 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 115 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subjects with retinal vascular abnormalities
Who may be able to join
- Any patient with abnormal retinal findings as determined by investigators.
Who cannot join
- Those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging.
- Participants who are unable to maintain retinal fixation on a specified target.
- Participants unable to achieve sufficient pupil dilation and alignment stability for imaging to take place.
- Patients with media opacity which preclude high quality imaging.
Trial locations and contacts
1 site in 1 country.
United States1 site
Stein Eye Institute/Geffen School of Medicine
Los Angeles, California, 90095
About this study
The purpose of this study is to evaluate this AngioScan angiography software on patients with various retinal vascular disorders. The advanced OCT instrument is an FDA approved clinically used camera, but the AngioScan angiography software is not FDA approved. Investigators would like to know if this imaging device and software can improve the quality of images and visualization of imaged tissues and whether they are useful in the diagnosis and treatment of eye diseases. Images collected in this study may be compared to other images collected as part of standard of care on the same patient (OCT, FA, AF, Fundus).
- Conditions
- Retinal Vascular Disorder, Macular Degeneration
- Medical subject headings
- Macular Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Retina abnormalities | Subjects with various retina vascular disorders |
What is being measured
The primary outcome is the main question the study is designed to answer.
Retinal vascular abnormalities imaged by OCT Angiography and en face analysis of macular disorders
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2016 (estimated)
- Study startJul 2016
- Primary completion9 Dec 2021
- Study completion9 Dec 2021
Why it stopped: Departmental priorities changed, partly due to COVID 19.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retinal Vascular DisorderStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02827071
- Sponsor's protocol ID
- JSEI Nidek Advanced OCT
- Status last verified
- Jul 2016
- First submitted
- 6 Jul 2016
- Last updated
- 20 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ocular Imaging Study Using Advanced OCT
- ClinicalTrials.gov ID
- NCT02827071
- Acronym / sponsor ID
- JSEI Nidek Advanced OCT
- Conditions
- Retinal Vascular Disorder, Macular Degeneration
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Departmental priorities changed, partly due to COVID 19.
- Enrolment
- 150 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Study start
- Jul 2016
- Primary completion
- 9 Dec 2021 (actual)
- Study completion
- 9 Dec 2021 (actual)
- First posted
- 11 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate this AngioScan angiography software on patients with various retinal vascular disorders. The advanced OCT instrument is an FDA approved clinically used camera, but the AngioScan angiography software is not FDA approved. Investigators would like to know if this imaging device and software can improve the quality of images and visualization of imaged tissues and whether they are useful in the diagnosis and treatment of eye diseases. Images collected in this study may be compared to other images collected as part of standard of care on the same patient (OCT, FA, AF, Fundus).
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Retina abnormalities | – | –Subjects with various retina vascular disorders |
Who may qualify
- Ages
- 18 to 115 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects with retinal vascular abnormalities
Key inclusion criteria (1 listed)
- Any patient with abnormal retinal findings as determined by investigators.
Key exclusion criteria (4 listed)
- Those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging.
- Participants who are unable to maintain retinal fixation on a specified target.
- Participants unable to achieve sufficient pupil dilation and alignment stability for imaging to take place.
- Patients with media opacity which preclude high quality imaging.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Retinal vascular abnormalities imaged by OCT Angiography and en face analysis of macular disorders
Time frame: 2 years
Results and safety
The study was stopped early (reason given: Departmental priorities changed, partly due to COVID 19.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Retinal Vascular Disorder
Active, not recruitingObservational study
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
Diabetic Macular Edema, Diabetic Retinopathy
Not yet recruitingObservational study
A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis
Age- Related Macular Degeneration, Diabetic Retinopathy
RecruitingPhase 2
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
Diabetic Macular Edema (DME)
RecruitingObservational study
National Eye Institute Biorepository for Retinal Diseases
Age-Related Macular Degeneration, Diabetic Retinopathy
RecruitingObservational study
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
Diabetes Complications, Diabetic Retinopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Retinal Vascular Disorder and Macular Degeneration, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 20 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Departmental priorities changed, partly due to COVID 19.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Retinal vascular abnormalities imaged by OCT Angiography and en face analysis of macular disorders (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2026.